

## WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Monday, June 12, 2006

<b>Hide?</b>	<b>Set Name</b>	<b>Query</b>	<b>Hit Count</b>
		<i>DB=PGPB,USPT; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L13	peroxochromate and L12	1
<input type="checkbox"/>	L12	rheumatoid and L11	396
<input type="checkbox"/>	L11	thiazole and L10	492
<input type="checkbox"/>	L10	arthritis and L9	1472
<input type="checkbox"/>	L9	11 or 12 or 13 or 14 or 15 or 16 or 17 or L8	7263
<input type="checkbox"/>	L8	548/518.ccls.	856
<input type="checkbox"/>	L7	548/469.ccls.	494
<input type="checkbox"/>	L6	548/146.ccls.	674
<input type="checkbox"/>	L5	544/133.ccls.	487
<input type="checkbox"/>	L4	514/422.ccls.	2057
<input type="checkbox"/>	L3	514/415.ccls.	1128
<input type="checkbox"/>	L2	514/365.ccls.	2391
<input type="checkbox"/>	L1	514/236.8.ccls.	273

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	9	MAR 22	EMBASE is now updated on a daily basis
NEWS	10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	12	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS	16	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	17	MAY 11	KOREAPAT updates resume
NEWS	18	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	19	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	20	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	21	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT <a href="http://download.cas.org/express/v8.0-Discover/">http://download.cas.org/express/v8.0-Discover/</a>
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:24:46 ON 12 JUN 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:25:01 ON 12 JUN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUN 2006 HIGHEST RN 887399-72-6

DICTIONARY FILE UPDATES: 11 JUN 2006 HIGHEST RN 887399-72-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10612187\Struc 5.str



```

chain nodes :
12 13 20 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 14 15 16 17 18 19
chain bonds :
10-12 12-13 13-22 15-22 20-23 23-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-11 7-8 8-9 9-10 10-11 14-19 14-15 15-16
16-17 17-18 18-19
exact/norm bonds :
7-11 7-8 8-9 9-10 10-11
exact bonds :
10-12 12-13 13-22 15-22 20-23 23-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-19 14-15 15-16 16-17 17-18 18-19

```

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 31:CLASS


```

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



10612187a.trn

Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 12:25:16 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 3627 TO ITERATE

55.1% PROCESSED 2000 ITERATIONS 1 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 68929 TO 76151  
PROJECTED ANSWERS: 1 TO 116

L2 1 SEA SSS SAM L1

=> l1 full

FULL SEARCH INITIATED 12:25:18 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 74070 TO ITERATE

100.0% PROCESSED 74070 ITERATIONS 16 ANSWERS  
SEARCH TIME: 00.00.01

L3 16 SEA SSS FUL L1

=> file medline caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'MEDLINE' ENTERED AT 12:25:22 ON 12 JUN 2006

FILE 'CAPLUS' ENTERED AT 12:25:22 ON 12 JUN 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)



=> l3

L4 2 L3


=> d ibib abs hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:41452 CAPLUS  
DOCUMENT NUMBER: 140:111408  
TITLE: Preparation of substituted heteroaryl and heterocyclic  
compounds useful NAD oxidase hydride donor inhibitors  
INVENTOR(S): Beers, Scott  
PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.  
SOURCE: PCT Int. Appl., 26 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005267	A2	20040115	WO 2003-US20781	20030702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003267980	A1	20040123	AU 2003-267980	20030702
US 2005014745	A1	20050120	US 2003-612187	20030702
PRIORITY APPLN. INFO.:			US 2002-393710P	P 20020703
			WO 2003-US20781	W 20030702
OTHER SOURCE(S):		MARPAT 140:111408		
GI				



II



III

AB The invention refers to substituted heteroaryl and heterocyclic compds. I [wherein: R<sup>1</sup> is a substituent on the 3, 4 or 5 position of the ring A and R<sup>1</sup> = H, alkyl, alkoxy, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, halogen, OH; A, E = phenylene or pyridinylene; B is a monocyclic 5-membered heteroarylene containing N, O, or S, and optionally containing an addnl. N; R<sup>2</sup>, R<sup>3</sup> = H, alkyl-R<sub>4</sub>, cycloalkyl; R<sub>4</sub> = alkoxy, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, 1-3 halogen(s), OH, cycloalkyl-R<sub>5</sub>, heterocyclyl-R<sub>5</sub>, (hetero)aryl-R<sub>5</sub>; R<sub>5</sub> = H, 1 or 2 of alkyl or alkoxy] and pharmaceutically acceptable salts thereof useful as NAD oxidase hydride donor inhibitors. Compds. I are claimed to be useful in treating or ameliorating reactive oxygen species-mediated inflammatory disorders such as osteoarthritis and Alzheimer's disease. In an NADPH oxidase assay for inhibition of superoxide-mediated reduction of cytochrome c in human neutrophils incubated with phorbol myristate acetate, 11 compds. I had IC<sub>50</sub> values of 0.04-3.45 μM. For instance, compound II (IC<sub>50</sub> = 1.65 μM) was prepared via heterocyclization of 4-ClC<sub>6</sub>H<sub>5</sub>C(O)CH<sub>2</sub>Br with H<sub>2</sub>NC(S)CO<sub>2</sub>Et, reduction of obtained thiazole III to the appropriate alc. analog, etherification with 3-HOC<sub>6</sub>H<sub>5</sub>CHO, and subsequent


reductive amination by propylamine.

IT 646053-15-8P, 3-[[4-(4-Chlorophenyl)-2-thiazolyl]methoxy]-N-propylbenzenemethanamine 646053-17-0P, 4-[[4-(4-Chlorophenyl)-2-thiazolyl]methoxy]-N-propylbenzenemethanamine 646053-18-1P, 3-[[4-(4-Chlorophenyl)-2-thiazolyl]methoxy]-N-(2-methylpropyl)benzenemethanamine 646053-19-2P, 3-[[4-(4-Chlorophenyl)-2-thiazolyl]methoxy]-N-cyclopentylbenzenemethanamine 646053-20-5P, 3-[[4-(4-Chlorophenyl)-2-thiazolyl]methoxy]-N-cyclohexylbenzenemethanamine 646053-21-6P, 3-[[4-(4-Chlorophenyl)-2-thiazolyl]methoxy]-N-cyclopropylbenzenemethanamine 646053-22-7P, N-[[3-[[4-(4-Chlorophenyl)-2-thiazolyl]methoxy]phenyl]methyl]-1-methyl-2-pyrrolidinemethanamine dihydrochloride 646053-23-8P, 4-[2-[[[3-[[4-(4-Chlorophenyl)-2-thiazolyl]methoxy]phenyl]methyl]amino]ethyl]morpholine dihydrochloride 646053-24-9P, 4-(4-Chlorophenyl)-2-[[3-[[[(5-methyl-2-furanyl)methyl]amino]methyl]phenoxy]methyl]thiazole 646053-25-0P, N-[[3-[[4-(4-Chlorophenyl)-2-thiazolyl]methoxy]phenyl]methyl]-5-methoxy-1H-indole-3-ethanamine hydrochloride 646053-26-1P, 4-[[4-(4-Chlorophenyl)-2-thiazolyl]methoxy]-N-cyclopentylbenzenemethanamine 646053-27-2P, 3-[[4-(4-Chlorophenyl)-2-thiazolyl]methoxy]benzenemethanamine 646053-30-7P 646053-31-8P 646053-32-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted heteroaryl and heterocyclic compds. as NAD oxidase hydride donor inhibitors useful in treating/ameliorating reactive oxygen species-mediated inflammatory disorders)


RN 646053-15-8 CAPLUS

CN Benzenemethanamine, 3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]-N-propyl- (9CI) (CA INDEX NAME)




RN 646053-17-0 CAPLUS

CN Benzenemethanamine, 4-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]-N-propyl- (9CI) (CA INDEX NAME)




RN 646053-18-1 CAPLUS

CN Benzenemethanamine, 3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 646053-19-2 CAPLUS

CN Benzenemethanamine, 3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 646053-20-5 CAPLUS

CN Benzenemethanamine, 3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]-N-cyclohexyl- (9CI) (CA INDEX NAME)



RN 646053-21-6 CAPLUS


CN Benzenemethanamine, 3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]-N-cyclopropyl- (9CI) (CA INDEX NAME)



RN 646053-22-7 CAPLUS


CN 2-Pyrrolidinemethanamine, N-[[3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]phenyl]methyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)






● 2 HCl

RN 646053-23-8 CAPLUS  
 CN 4-Morpholineethanamine, N-[[3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]phenyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 646053-24-9 CAPLUS  
 CN 2-Furanmethanamine, N-[[3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]phenyl]methyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 646053-25-0 CAPLUS  
 CN 1H-Indole-3-ethanamine, N-[[3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]phenyl]methyl]-5-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● HCl


PAGE 1-B

— Cl


RN 646053-26-1 CAPLUS  
 CN Benzenemethanamine, 4-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 646053-27-2 CAPLUS  
 CN Benzenemethanamine, 3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 646053-30-7 CAPLUS  
 CN 2-Pyrrolidinemethanamine, N-[[3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]phenyl]methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 646053-31-8 CAPLUS  
 CN 4-Morpholineethanamine, N-[[3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 646053-32-9 CAPLUS  
 CN 1H-Indole-3-ethanamine, N-[[3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]phenyl]methyl]-5-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Cl


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1999:9818 CAPLUS  
 DOCUMENT NUMBER: 130:66488  
 TITLE: Preparation and formulation of heterocyclic moiety-containing sulfamoylbenzoic acid derivatives as LTD4 and thromboxane A2 antagonists  
 INVENTOR(S): Ichikawa, Yoshihiro; Nishida, Tokiko; Nakano, Jun; Watanuki, Mitsuru; Suda, Masahiro; Nakamura, Tsutomu  
 PATENT ASSIGNEE(S): Kaken Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 96 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent

10612187a.trn

LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857935	A1	19981223	WO 1998-JP2585	19980612
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2294956	AA	19981223	CA 1998-2294956	19980612
AU 9876744	A1	19990104	AU 1998-76744	19980612
AU 732106	B2	20010412		
EP 999209	A1	20000510	EP 1998-924585	19980612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 3527514	B2	20040517	JP 1999-504121	19980612
US 6255321	B1	20010703	US 1999-445976	19991215
US 6376671	B2	20020423	US 2001-844095	20010427
US 2002049228	A1	20020425		
JP 2004137284	A2	20040513	JP 2003-398975	20031128
PRIORITY APPLN. INFO.:			JP 1997-176458	A 19970617
			JP 1999-504121	A3 19980612
			WO 1998-JP2585	W 19980612
			US 1999-445976	A3 19991215

OTHER SOURCE(S): MARPAT 130:66488  
 GI



AB The title compds. I [R1, R2 = H, cycloalkyl, etc.; further details on R1 and R2 are given; A = OB, etc.; B = alkylene, etc.; a proviso is given; X = S, etc.; R3 = (un)substituted phenylsulfonylamino, etc.; R4 = H, etc.; n = 2 - 6] are prepared In an in vitro test for thromboxane A2 receptor antagonism, the title compound I [R1 = isopropyl; R2 = R4 = H; A = CH2O; R3 = p-chlorobenzenesulfonylamino; n = 4; X = S] showed the pA2 value of 8.3.

IT 217800-45-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of heterocyclic moiety-containing sulfamoylbenzoic acid derivs. as

LTD4 and thromboxane A2 antagonists)

RN 217800-45-8 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[4-[[[3-[(4-phenyl-2-

thiazolyl)methoxy]phenyl)methyl]amino]butyl] - (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

$$\Rightarrow \log y$$

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

19.71

186.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

## SESSION

CA SUBSCRIBER PRICE

-1.50

-1.50

STN INTERNATIONAL LOGOFF AT 12:38:04 ON 12 JUN 2006